HOUSTON & LAS VEGAS--(BUSINESS WIRE)--Today at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology, BRI announced encouraging results from the ongoing Phase II clinical trials of two of its investigational drugs, Atengenal (A10) and Astugenal (AS2-1), defined as antineoplastons therapy (ANP). The meeting is currently taking place in Loews Lake, Las Vegas, Nevada.
